Icon
+91 94997 68112
Login Register

Saphris - (5, 10 mg; Tablet, Sublingual)

ASENAPINE MALEATE Forest
5, 10 mg; Tablet, Sublingual
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
Acute treatment of manic or mixed episodes associated with bipolar I disorder, as monotherapy or adjunctive therapy with lithium or valproate.
Yes
********(******) *** ******** ***** *** **** ** ****** ** ******* *** **** ***** *** **** ** ************ ** ***. ********** **** ** ** *** *** ** ** ***** **** ** **** ******* ‘*** (**** *, ****) *** ‘*** (***** *, ****). ******* *****, ************, ******* *** ****** **** ***** **** ** **** **** ******* *** **** ************ *********. * ******** *** ****** ** ***** ** ****** ***** *** ******** ***** ***** ****** '*** ** ***** *** ********* ** *** *** ********** ****** ***** ******. *****, ********* *** ****** '*** ****** *** ******* ** ***** ** ****** ************ *** ******* ***** *****, ******, *****, ******* *** ************ **** '*** ****** ** *****. **** ****** ** ****** **.***. *** ****** *** *** ***** * **** ** *** *** ********* *** ******** ***** ** ***** ************** ** *********** **** *******. *******, ***********, *** ************ ******** *** ******* ** *** ****. ***** ********* *** ****** ******* ******* **** *** ****
Saphris Patent 1 Patent 2 Patent 3
*********** **** ** ** ******* *** *********
***** **** ** ** ******* *******
************ **** ** ** ******* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*********** *** \ ** ***** *, **** **** ** **/******* ******** ******** ** *** **, ****
***** ***\ ** ***** *, **** **** ** **/******* **** ****** **** ********
************ *** \ ** **** **, **** **** ** **/******* ******** ******** ** *** ****
  1. *** **, **** : ***** ****** ***** ** **** **** **** ** ** *** ***.
  2. *** *, **** : ***** ****** ******** ****** **** ***** *** **** ** **** ******* ‘*** (**** *, ****) *** ‘*** (***** *, ****).
  3. *** *, **** : ****** **** ***** * **** ******* ***** ****** ** ******** ***** ** ********.
  4. *** **, **** : ***** ******** ****** ***** *** **** ** **** ******* ‘*** (**** *, ****), ‘*** (***** *, ****) *** ******* (*** *, ****)
  5. *** *, **** : ****** ***** * **** ******* ***** ** ******* ‘*** (***** *, ****), '*** (**** *, ****) *** '*** (*** *, ****)
  6. *** **, **** : ************ ******** ****** ***** *** **** ** **** ******* ******* ‘*** (**** *, ****) *** ‘*** (***** *, ****).
  7. *** **, **** : ****** ***** * **** ******* ************ ** ******** ***** ** ********.
  8. *** **, **** : ******* ******** ****** ***** *** **** ** **** ******* ******* ‘*** (**** *, ****) *** ‘*** (***** *, ****).
  9. *** **, **** : ****** ***** * **** ******* ******* ** ******** ***** ** ********.
  10. *** **, **** : ****** ******** ****** ***** *** **** ** **** ******* ******* ‘*** (**** *, ****) *** ‘*** (***** *, ****).
  11. *** **, **** : ****** ***** * **** ******* ****** ** ******** ***** ** ********.
  12. *** *, **** : ****** ***** ** ******* ********* ******* ***** ** *** *******
  13. ** ** **** : ****** ************ ******* ** ******* ***** **** ***** ******* *** ********* ** ****** '*** *** '***.
  14. *** *, **** : ********* *** ****** *,***,*** ("*** '*** ******") *** ******* ** ***** ** ****** ************ *** ******* *** **********. ** ** ************ ** *** ******** ****** ** *** '*** ******: *. ** ***********, ******** ** ************ ** ****** *, *, * *** * ** *** '*** ****** *** ******* ** ***** ** ********** *** ******* *** ********** ***** **** **********. *. ** ***********, ******** ** ************ ** ****** *, *, *** ** *** ******* ** ***** ** ********** *** ******* *** ****** *** ***** **********. *. ******** ** ***-************ ** ****** *, *, *** ** *** ******* ** ***** ** *** ******* *** ************ ********** *** ******* **********.
  15. *** **, **** : *** *** ********** ***** **** ***** ****** *.*. *******, ************, ***** *** ****** ******** *** ******** ** ******* *******.
  16. *** **, **** : ******* ***** ******** ******** *****'* ******** *** ****** '***
  17. *** **, **** : ******* *** ********* ********.*****://***.**********.***.***/**********_****/*********/****/********************.***
  18. *** **, **** : ********* *** ****** *,***,*** ("*** '*** ******") *** ******* ** ***** ** ****** ************ *** ******* ***** ***** **** '*** ****** ** *****
  19. **** **, **** : ***** ***** *** ***** ********. *****://***.**********.***.***/**********_****/*********/****/******************.***
  20. *** **, **** : * ***** ********* ** ******* ** ***** ** ****** *** ******* ******, *****, ******* *** ************ ** ****** '*** *** ********* **** ** *** ***** ******** ** ***** **** ****** ***'* ** ******* ***** ********** ** ****** '***
  21. *** **, **** : ************ *** ******* *** ***** ********.

Saphris - (2.5 mg; Sublingual, Tablet)

ASENAPINE MALEATE Forest
2.5 mg; Sublingual, Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
Acute treatment of manic or mixed episodes associated with bipolar I disorder, as monotherapy or adjunctive therapy with lithium or valproate It is used for monotherapy in pediatric patients: The recommended dose of SAPHRIS is 2.5 mg to 10 mg twice daily in pediatric patients 10 to 17 years of age, and dose may be adjusted for individual response and tolerability.
Yes
****** *** ******** ** ************ ***** **'* **** ** ****** ** ****** '*** (**** ******* ** ********** *******, *****. ** *.* ** ****) . **** *** ** ********* ** **** **. ****** (*** *** ********** ***********, ***, *** **** ** ********* ******* ******* *****. ** * ** **** *** *****. ** ** ** ****). *******, ****** ************ ***** * **** ******* ************ ** ****** '*** *** ***** ********** ** *******. *** ***** ****** **** ******** **** ** ********** *** ********* *********** ******* ** *** **, **** .************ *** ***** ********.
Saphris Patent 1 Patent 2 Patent 3
************ **** ** ** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
************ *** \ ** ***** *, **** **** ** ** ******** ******** ** *** **, ****
  1. *** **, **** : ************ ***** **** *** ******** ******** (******) ***** **'* **** ** ****** ** ****** '*** (**** *, ****)
  2. *** **, **** : ****** ************ ***** * **** ******* ************ ** ****** '***.
  3. *** **, **** : ************ ******** ******** **** ** *** ********* **** **. ******, *** ******** *********** ******** ** ** *.*.*. § ***(*)(*)(*).
  4. *** **, **** : ************ ***** ******** ****** ***** *** **** ****** *** ******** ** ** ******** ****** ****** ***** *** **, ****
  5. *** **, **** : ******** (******) ***** * **** ******* ************ ** ****** '***
  6. *** **, **** : ****** ************ ***** * **** ******* ************ ** ****** '***.
  7. *** **, **** : ************ *** ***** ********.
  8. *** **, **** : * ***** ********* ** ******* ** ***** ** ****** *** ******* ************ ** ****** '*** *** ********* **** ** *** ***** ******** ** ***** **** ***** ***'* ** ******* ***** ********** ** ****** '***

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.